Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2016 08:00 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study

Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
May 25, 2016 08:00 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with BeadTek™

MORRISTOWN, N.J., May 25, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark...
May 11, 2016 08:00 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Announces CEO Transition

MORRISTOWN, N.J., May 11, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with...
May 09, 2016 08:00 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Overcomes Challenge to Treximet® ‘183 Patent

MORRISTOWN, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and...
May 05, 2016 08:00 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update

Pernix Prescriptions DirectTM Achieves Increased Penetration MORRISTOWN, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a...
April 28, 2016 08:30 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016

MORRISTOWN, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release financial results for...
April 05, 2016 16:01 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference

MORRISTOWN, N.J., April 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief...
March 10, 2016 08:00 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update

Full Year 2015 Revenue Increases 44% Year-Over-Year to $176 MillionFull Year 2015 Adjusted EBITDA of $31.2 MillionMORRISTOWN, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings,...
March 02, 2016 08:30 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Files Citizen Petition Following Issuance of U.S. Patent Number 9,265,760 (‘760 Patent) Covering Safety Information Related to Dosing Patients with Zohydro ER® with BeadTek™ CII

Morristown, NJ, March 02, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced their submission of a Citizen Petition to...
February 24, 2016 08:43 ET | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics to Report Fourth Quarter and Full-Year 2015 Financial Results on Thursday, March 10, 2016

MORRISTOWN, N.J., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release its fourth quarter and...